31698-14-3
Chemical Structure
Ancitabine
Synonym(s): Cyclocytidine; Cyclo-CMP
- CAS No.: 31698-14-3
- Formula:C9H11N3O4
- Molecular Weight:225.20
IUPAC Name: (2R,3R,3aS,9aR)-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydro-6H-furo[2',3':4,5]oxazolo[3,2-a]pyrimidin-3-ol
InChIKey: BBDAGFIXKZCXAH-CCXZUQQUSA-N
SMILES: OC[C@@H]1[C@@H](O)[C@@](O2)([H])[C@@](N(C2=N3)C=CC3=N)([H])O1
Biological Activity: Ancitabine (Cyclocytidine) is a cytarabine derivative that inhibits viral replication. Ancitabine blocks vaccinia virus DNA replication, the progression of viral protein synthesis from early to late stages, and one-step growth of vaccinia virus. Ancitabine is applicable to research related to vaccinia virus infection, leukemia, human cytomegalovirus infection and colorectal cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ancitabine | Ancitabine (Cyclocytidine) is a cytarabine derivative that inhibits viral replication. Ancitabine blocks vaccinia virus DNA replication, the progression of viral protein synthesis from early to late stages, and one-step growth of vaccinia virus. Ancitabine is applicable to research related to vaccinia virus infection, leukemia, human cytomegalovirus infection and colorectal cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Deng L, et al. Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virol. 2007;81(24):13392-13402. [Content Brief]
- [2]. Nakamura K, et al. Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus. J Med Virol. 1990;31(2):141-147. [Content Brief]
- [3]. Aftab O, et al. Detection of cell aggregation and altered cell viability by automated label-free video microscopy: a promising alternative to endpoint viability assays in high-throughput screening. J Biomol Screen. 2015;20(3):372-381. [Content Brief]
